Who Is Cann? A Brand File on the Celebrity-Backed THC Drink

Cann is the rare brand that's genuinely transparent about two of the hardest things — its lab testing and its funding — and genuinely opaque about a third: who actually makes the product. And it carries a confirmed regulatory blemish that a great COA program is supposed to prevent. That combination is exactly why a category leader lands at a C.

Credit where it's due: Cann posts full-panel, batch-specific Certificates of Analysis from a named, accredited lab, and it's openly venture-backed with named investors — both well above industry norm. The deductions are specific: it won't name its contract manufacturer, and in 2025 a California prosecutor obtained a $115,000 settlement over drinks whose THC and CBD content didn't match the label. We'll walk all of it.

Cann operates under SOCALI Manufacturing, Inc., and was founded around 2018–2019 by Jake Bullock (CEO, a former Bain & Company consultant) and Luke Anderson — both with elite-school backgrounds. It's based in the Venice/Los Angeles area, with an Austin, Texas nexus on some filings.

Here's the gap. Despite the "Manufacturing, Inc." in its legal name, Cann appears to rely on third-party co-packers — the settlement documents (below) reference "SoCali's manufacturing partners." The company does not name that co-packer or emulsion partner, and we found no published GMP certification. For a beverage that's been found to have label-accuracy problems, knowing who runs the production line — and whether that facility is audited — matters a lot, and it's information Cann doesn't give you.

This is where Cann shines, and we won't undersell it. Cann publishes third-party Certificates of Analysis that are batch-specific and full-panel — we verified an actual COA (a Lemon Lavender batch) covering cannabinoids, pesticides (66 analytes), microbials, mycotoxins, heavy metals, residual solvents, and foreign matter, all passing. The lab is named — California Ag Labs, an ISO-17025-accredited facility — and the COAs are publicly hosted. That is a better lab-disclosure posture than the large majority of brands we examine, including some that score higher overall.

This is a documented fact, not an allegation, so we state it plainly. In September 2025, the Monterey County (California) District Attorney announced a settlement in which SOCALI Manufacturing (Cann) agreed to pay $115,000 — $90,000 in civil penalties plus $25,000 in investigative costs. The civil complaint alleged false advertising of cannabinoid content: products labeled (for example) 2mg THC / 4mg CBD were found, across California, to vary by more than 10% from their stated amounts — both over and under. As part of the settlement, Cann was ordered to implement quality-control measures with its manufacturing partners.

To be precise about what this is and isn't: it's a civil settlement, sourced directly to the District Attorney's own announcement — a real, resolved regulatory action, which is why it weighs on Cann's record. It is not a criminal conviction, and "over and under" means some cans had less THC than labeled, not necessarily more. But for a product you dose by the milligram, a regulator finding your labels off by 10%+ is a material consumer-protection issue, and it's the single biggest reason Cann's score sits where it does. Separately, an unrelated 2023 website-accessibility (ADA) lawsuit against the company was voluntarily dismissed.

Ingredients are clean and clearly listed — reverse-osmosis sparkling water, agave, citrus, and hemp-derived THC/CBD extract — though Cann doesn't name its specific hemp supplier. People: it's a US-based operation, but headcount isn't reliably disclosed (databases show outdated low figures for a brand selling millions of cans), and its Glassdoor sits around 2.5/5 on a very small sample with some layoff complaints, which we weight as low-confidence. We found no evidence of overseas labor.

Customers and record: Cann is a genuine market leader — the #1 THC beverage in California by sales, in Total Wine in ~20 states, with a Target pilot — and consumer reviews of the taste and effect are generally positive (with recurring shipping gripes on a tiny Trustpilot sample). No FDA warning letter or recall was found. The market success is real; so is the DA settlement. We report both.

In our view, Cann is a paradox worth understanding before you buy: it's more transparent than most brands on lab testing and funding, and it still shipped products a prosecutor found were mislabeled. If you value rigorous, accredited, batch-level COAs and openness about who's funding the company, Cann genuinely delivers those. If your priority is knowing exactly who manufactures your drink and trusting that the label matches the can, the unnamed co-packer and the 2025 settlement are real reasons for pause.

We've graded it a C (71/100) — the lab and funding transparency keep it out of the basement; the manufacturing opacity and the confirmed regulatory action keep it out of the B's. It's a fixable profile: name the manufacturer, document the QC the DA ordered, and this rises. The full methodology shows every point. (And if Cann can show us the corrective steps it has taken since the settlement, we'll update the file — see the notice below.)